West Pharmaceutical Services WST Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Proprietary Products | $694.3M+4.9% | $661.8M+2.2% | $647.5M+4.5% | $619.8M+10.1% | $563M-8.3% | |
| West Vantage | $150.6M— | —— | —— | —— | $135M— | |
| Other segment expense (income) by Business | ||||||
| Proprietary Products | $3.1M-48.3% | $6M-1.6% | $6.1M+1.7% | $6M+100% | $3M-74.6% | |
| West Vantage | -$100K— | —— | —— | —— | $600K— | |
| Total Assets by Business | ||||||
| Proprietary Products | $2.93B-1.8% | $2.99B-0.1% | $2.99B+5.7% | $2.83B+7.8% | $2.63B+0.2% | |
| West Vantage | $739.6M+3.0% | $718.1M— | —— | —— | —— | |
| Operating Income (Loss) by Business | ||||||
| Proprietary Products | $189.2M-0.3% | $189.7M+8.3% | $175.2M+8.3% | $161.7M+23.8% | $130.6M-19.5% | |
| West Vantage | $15.6M— | —— | —— | —— | $13.5M— | |
| Selling, general and administrative expenses by Business | ||||||
| Proprietary Products | $65M-4.7% | $68.2M+4.0% | $65.6M+6.7% | $61.5M+2.0% | $60.3M+3.8% | |
| West Vantage | $7.8M— | —— | —— | —— | $7.6M— | |
| Cost of goods and services sold by Business | ||||||
| Proprietary Products | $421.2M+12.0% | $376.1M-1.9% | $383.5M+3.2% | $371.5M+5.3% | $352.8M-2.9% | |
| West Vantage | $127.3M— | —— | —— | —— | $113.3M— | |
| Capital Expenditures by Business | ||||||
| Proprietary Products | $36.5M-35.1% | $56.2M+17.8% | $47.7M-1.6% | $48.5M-6.6% | $51.9M-34.4% | |
| West Vantage | $5.6M— | —— | —— | —— | $18.1M— | |
| R&D by Business | ||||||
| Proprietary Products | $15.8M-27.5% | $21.8M+27.5% | $17.1M-10.5% | $19.1M+17.2% | $16.3M-11.9% | |
| West Vantage | $0— | —— | —— | —— | $0— | |
| Depreciation and Amortization by Business | ||||||
| Proprietary Products | $36.4M-5.9% | $38.7M+10.3% | $35.1M+4.2% | $33.7M+3.1% | $32.7M-2.4% | |
| West Vantage | $8M— | —— | —— | —— | $6.4M— | |
| Concentration risk, percentage by Product | ||||||
| High-Value Product ("HVP") Components | 48%— | —— | 48%+1.0pp | 47%+2.0pp | 45%— | |
| High-Value Product ("HVP") Delivery Devices | 15%— | —— | —— | —— | 14%— | |
| Standard Packaging | 19%+11.0pp | 8%-4.0pp | 12%-1.0pp | 13%-9.0pp | 22%+12.0pp | |
| West Vantage | 18%— | —— | —— | —— | 19%— | |
| Concentration risk, percentage by Geography | ||||||
| Americas | 45%— | —— | 47%+2.0pp | 45%-4.0pp | 49%+48.0pp | |
| Asia Pacific | 8%+7.0pp | 1%-7.0pp | 8%-1.0pp | 9%+2.0pp | 7%— | |
| Europe, Middle East, Africa | 47%— | —— | 45%-1.0pp | 46%+2.0pp | 44%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does West Pharmaceutical Services break its business down?
- West Pharmaceutical Services (WST) reports net sales by business across 2 parts — Proprietary Products and West Vantage. Each is extracted from the segment footnotes and tracked over time.
- Where does West Pharmaceutical Services's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in West Pharmaceutical Services's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
